Literature DB >> 29967022

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.

Emily L Heil1, David P Nicolau2, Andras Farkas3,4, Jason A Roberts5,6, Kerri A Thom7.   

Abstract

This was a prospective study to determine if pharmacokinetic/pharmacodynamic (PK/PD)-based antibiotic dosing software aids in achieving concentration targets in critically ill patients receiving cefepime (n = 10), meropenem (n = 20), or piperacillin-tazobactam (n = 19). Antibiotic calculator doses targeting a >90% probability of target attainment (PTA) differed from package insert doses for 22.4% (11/49) of patients. Target attainment was achieved for 98% of patients (48/49). A PK/PD-based antibiotic dosing calculator provides beta-lactam doses with a high PTA in critically ill patients.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  beta-lactam; critically ill; pharmacodynamic; pharmacokinetic

Mesh：

Substances：

Year:  2018        PMID： 29967022      PMCID： PMC6125501          DOI： 10.1128/AAC.01008-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  High-performance liquid chromatographic assay for meropenem in serum.

Authors:  H Elkhaïli; S Niedergang; D Pompei; L Linger; D Leveque; F Jehl
Journal:  J Chromatogr B Biomed Appl       Date:  1996-11-08

3.  High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.

Authors:  F Lamoth; T Buclin; A Pascual; S Vora; S Bolay; L A Decosterd; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

Authors:  D S Burgess; R W Hastings; T C Hardin
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

5.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Authors:  Christine T Ong; Pamela R Tessier; Chonghua Li; Charles H Nightingale; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2006-08-23       Impact factor: 2.803

6.  Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients.

Authors:  Gloria Wong; Andras Farkas; Rachel Sussman; Gergely Daroczi; William W Hope; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

7.  MIC-based dose adjustment: facts and fables.

Authors:  Johan W Mouton; Anouk E Muller; Rafael Canton; Christian G Giske; Gunnar Kahlmeter; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

Review 8.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Authors:  Joao Gonçalves-Pereira; Pedro Póvoa
Journal:  Crit Care       Date:  2011-09-13       Impact factor: 9.097

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925
View more
  12 in total

Review 1.  Optimising antimicrobial therapy through the use of Bayesian dosing programs.

Authors:  M L Avent; B A Rogers
Journal:  Int J Clin Pharm       Date:  2019-08-07

2.  Personalized antibiotic dosing for the critically ill.

Authors:  Jason A Roberts; Claire Roger; Jan J De Waele
Journal:  Intensive Care Med       Date:  2019-01-14       Impact factor: 17.440

3.  Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.

Authors:  Ashlan J Kunz Coyne; Mohammad Alshaer; Anthony M Casapao; Veena Venugopalan; Carmen Isache; Jason Ferreira; Christopher A Jankowski
Journal:  Antimicrob Agents Chemother       Date:  2022-09-08       Impact factor: 5.938

4.  Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Ze-Ming Wang; Xiao-Yu Chen; Wei Zhao; A-Dong Shen; Jing Bi; Mei-Ying Wang; Bao-Ping Xu; Bo-Hao Tang; Cen Li
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

5.  Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.

Authors:  Jörn Grensemann; David Busse; Christina König; Kevin Roedl; Walter Jäger; Dominik Jarczak; Stefanie Iwersen-Bergmann; Carolin Manthey; Stefan Kluge; Charlotte Kloft; Valentin Fuhrmann
Journal:  Ann Intensive Care       Date:  2020-04-22       Impact factor: 6.925

Review 6.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

7.  Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.

Authors:  Luca F Roggeveen; Lucas M Fleuren; Tingjie Guo; Patrick Thoral; Harm Jan de Grooth; Eleonora L Swart; Thomas L T Klausch; Peter H J van der Voort; Armand R J Girbes; Rob J Bosman; Paul W G Elbers
Journal:  Trials       Date:  2019-12-18       Impact factor: 2.279

8.  Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia.

Authors:  Abdullah Alsultan; Shereen A Dasuqi; Fadi Aljamaan; Rasha A Omran; Saeed Ali Syed; Turki AlJaloud; Abdullah AlAhmadi; Saeed Alqahtani; Mohammed A Hamad
Journal:  Saudi Pharm J       Date:  2021-10-08       Impact factor: 4.330

9.  Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring-A Descriptive Retrospective Analysis.

Authors:  Schrader Nikolas; Riese Thorsten; Kurlbaum Max; Meybohm Patrick; Kredel Markus; Surat Güzin; Scherf-Clavel Oliver; Strate Alexander; Pospiech Andreas; Hoppe Kerstin
Journal:  Antibiotics (Basel)       Date:  2021-11-26

10.  Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study.

Authors:  Guangna Cao; Pengxiang Zhou; Hua Zhang; Bangkai Sun; Xiaomei Tong; Yan Xing
Journal:  Antibiotics (Basel)       Date:  2022-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.